comparemela.com

Latest Breaking News On - J clin microbiol - Page 7 : comparemela.com

Mycovia Pharmaceuticals Submits New Drug Application to the U S FDA for Oteseconazole for the Treat

Search jobs 01-Jun-2021 Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis - NDA supported by positive data from VIOLET and ultraVIOLET Phase 3 clinical trials evaluating oteseconazole in more than 870 women in 11 countries - - Oteseconazole’s Qualified Infectious Disease Product and Fast-Track designations allow for six-month priority review by FDA following its acceptance of the NDA - DURHAM, N.C. (BUSINESS WIRE) Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced it has submitted its New Drug Application (NDA) for oteseconazole, an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC). Also known as chronic yeast infection, RVVC is a debilitating inf

A vaccination that is expected to prevent the spread of the disease can instead foster the spread of the disease

Background Although vaccination can be a useful tool for control of avian influenza epidemics, it might engender emergence of a vaccine-resistant strain. Field and experimental studies show that some avian influenza strains acquire resistance ability against vaccination. We investigated, in the context of the emergence of a vaccine-resistant strain, whether a vaccination program can prevent the spread of infectious disease. We also investigated how losses from immunization by vaccination imposed by the resistant strain affect the spread of the disease. Methods and Findings We designed and analyzed a deterministic compartment model illustrating transmission of vaccine-sensitive and vaccine-resistant strains during a vaccination program. We investigated how the loss of protection effectiveness impacts the program. Results show that a vaccination to prevent the spread of disease can instead spread the disease when the resistant strain is less virulent than the sensitive strain. If th

Saliva as a gold-standard sample for SARS-CoV-2 detection

Saliva as a gold-standard sample for SARS-CoV-2 detection
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study

Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Ebola: The New Fake Outbreak - LewRockwell

Ebola: The New Fake Outbreak We’re being warned that a new Ebola outbreak is spreading. Yahoo News (February 26, 2021): “On Feb. 17, the World Health Organization reported a cluster of Ebola cases in Guinea…The Biden administration is moving forward with plans to screen airline passengers from two African countries arriving in the U.S. for Ebola…” Before yet another lunatic pandemic story takes off, people need to understand the multiple hoaxes behind Ebola. I covered the story in 2017 and 2014. Here are the essential quotes from my pieces. Buckle up: There is one predictable outcome: at Congo clinics and hospitals, frightened people who arrive with what are labeled “early signs” of Ebola will be diagnosed as probable cases. What are those symptoms? Fever, chill, sore throat, cough, headache, joint pain. Sound familiar? Normally, this would just be called the flu.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.